Detection Of Tumor Markers Research Articles

A micro-chamber free digital bio-detection for multiplexed and ultrasensitive immunoassay based on encoded magnetic microbeads and tyramide signal amplification strategy

Digital bio-detection has become one of the most appealing methods in recent years due to its excellent performance with ultra-sensitivity in detection of low-abundance targets. Traditional digital bio-detection needs the utilization of micro-chambers for physical isolation of targets, while the recently developed beads-based micro-chamber free one is attracting extensive attention, although there exist the disadvantages of overlaps between positive (“1”) and negative (“0”) signals as well as the decreased detection sensitivity in multiplexed mode. Here we propose a feasible and robust micro-chamber free digital bio-detection for multiplexed and ultrasensitive immunoassay based on encoded magnetic microbeads (EMMs) and tyramide signal amplification (TSA) strategy. An EMMs-based multiplexed platform is constructed by using a fluorescent encoding method, then a puissant signal amplification of positive events in TSA procedure is achieved via systematical revelation of key factors influences. For proof of concept, a three-plexed tumor markers detection is performed to evaluate our established platform. The detection sensitivity is comparable to the corresponding single-plexed assays and is also approximately 30–15,000 times improvement compared to the conventional suspension chip. Therefore, this multiplexed micro-chamber free digital bio-detection paves a promising way to be an ultrasensitive and powerful tool for clinical diagnosis.

Significance of tumor markers combined with neutrophil to lymphocyte ratio, D-dimer and T-lymphocyte in the diagnosis of colon cancer.

To analyze the value of combined detection of tumor markers, neutrophil to lymphocyte ratio (NLR), D-dimer and T lymphocyte in the diagnosis of colon cancer. This is a retrospective study. A total of 80 patients with colon cancer and 80 patients with benign colon mass admitted to Baoding NO.1 Central Hospital from June 10, 2021 to December 10, 2022 were divided into the study group and the control group. Further comparison was performed on the tumor markers, NLR, D-dimer and T-lymphocyte levels between the two groups, associated with the comparison of corresponding levels of colon cancer at different stages. In addition, correlation analysis was carried out focusing on the above indicators with colon cancer. Carcinoembryonic antigen (CEA), CA199, NLR, D-dimer and CD8+ cell count levels in the study group were significantly higher than those in the control group, while CD4+ cell count and CD4+/CD8+ ratio were obviously lower (P<0.05). Among I-IV colon cancer, the highest levels of CEA, CA199, NLR, D-dimer, CD4+ and CD4+/CD8+ ratio were found in patients with Stage-IV colon cancer, while the level of CD8+ was the lowest (P<0.05). Correlation analysis indicated that CEA, CA199, NLR, D-dimer and CD8+ were positively correlated with whether the patient had colon cancer (r=0.841, 747,991,889,565, all P<0.05), but negative correlations with CD4+ and CD4+/CD8+ ratio (r=-0.999, -0.994, all P<0.05). The detection of tumor markers combined with NLR, D-dimer and T-lymphocytes has reference value in the diagnosis of colon cancer.

Background-free and signal-amplified upconversion fluorescent biosensing platform for sensitive detection of CYFRA21-1

Accurate and ultrasensitive detection of cytokeratin 19 fragment (CYFRA21-1) is of vital importance for screening and diagnosis of potential lung cancer patient. In this paper, surface-modified upconversion nanomaterials (UCNPs) capable of aggregation by atom transfer radical polymerization (ATRP) were used as luminescent materials for the first time to achieve signal-stable, low-biological background, and sensitive detection of CYFRA21-1. Upconversion nanomaterials (UCNPs) feature extremely low biological background signals and narrow emission peaks, making them ideal sensor luminescent materials. The combination of UCNPs and ATRP not only improves sensitivity, but also reduces biological background interference for detecting CYFRA21-1. The target CYFRA21-1 was captured by specific binding of the antigen and the antibody. Subsequently, the end of the sandwich structure with the initiator reacts with monomers modified on UCNPs. Then, massive UCNPs are aggregated by ATRP that amplify the detection signal exponentially. Under optimal conditions, a linear calibration plot of the logarithm of CYFRA21-1 concentration versus the upconversion fluorescence intensity was obtained in the range of 1 pg/mL to 100 μg/mL with a detection limit of 38.7 fg/mL. The proposed upconversion fluorescent platform can distinguish the analogues of the target with excellent selectivity. Besides, the precision and accuracy of the developed upconversion fluorescent platform were verified by clinical methods. As an enhanced upconversion fluorescent platform of CYFRA21-1, it is expected to be useful in screening potential patients with NSCLC and provides a promising solution for the high-performance detection of other tumor markers.

Application Of Quantum Dot Fluorescent Dyeing Technology in Tumor Detection

As a high-incidence disease, the tumor poses a huge threat to human health today. The timely and efficient detection of tumors is of great significance to improving the cure rate and improving people's health. Quantum dots have advantages of high fluorescence intensity, good stability and good biocompatibility, providing a new research approach for the detection of tumor markers. This paper reviews the application of quantum dots fluorescent dyeing technology in biosensing, imaging, tumor detection and treatment, which provides a reference for the development of tumor detection technology.

Nitrogen-doped dodecahedral hollow carbon combined with amplification strategy to construct ultra-sensitive self-powered biosensor for highly stable and real-time monitoring microRNA

MicroRNAs (miRNAs) are closely bound up with the occurrence and deterioration of some cancers, and their early diagnoses have aroused great interest. However, stable and ultra-sensitive real-time detection remains challenge. In this work, we report a strategy for real-time ultrasensitive detection of miRNA-21 by capacitor/enzymatic biofuel cell based self-powered biosensor (EBFC-SPB) with hybridization chain reaction (HCR) for signal amplification. The nitrogen doped dodecahedral hollow carbon (N-DHC) is used for high load, exonuclease III (EXO III)-aided target cells for accurate recognition, and HCR for signal amplification. In addition, the detected signals are further enhanced by a good match with the commercial capacitor, and the real-time portable detection of tumor markers can be achieved by directly reading the data with an Android smartphone. The detection limit of the method is 0.04 fM (S/N = 3) in the linear range of 0.01–5.0 × 103 fM. This method provides reference and theoretical support for the early diagnosis of related tumor markers.

Abstract 5599: An introduction of a highly sensitive circulating tumor DNA monitoring system for minimal residual disease detection using a library of 1000 digital PCR probes

Abstract Background: Many patients undergo a next generation sequencing (NGS)-based cancer genome profiling (CGP) test, but it often does not aid in choosing an optimal therapeutic regimen. Therefore, the genomic information should be used for minimal residual disease (MRD) detection, which directly leads to improved post-treatment cancer patient management. Circulating tumor DNA (ctDNA) is a small fraction of DNA present in blood that carries somatic mutations in cancer patients. Our previous studies demonstrated the clinical validity of ctDNA as a tumor marker for MRD detection. However, the variant allele frequency (VAF; reflecting the fraction of somatic mutations) of ctDNA is less than 1%, at which stable detection is difficult for NGS. Instead of NGS, we have established a highly sensitive ctDNA monitoring system for MRD detection using an originally developed library of &amp;gt;1000 digital PCR (dPCR) probes. Patients and Methods: Using a Clinical Institutional Review Board approval from the Iwate Medical University Hospital, we initiated a dPCR assay system, called off-the-shelf (OTS)-Assay, in April 2022 under a partnership with Quantdetect, Inc (Tokyo, Japan). The OTS-Assay has three main components: OTS-Scan, OTS-Select, and OTS-Monitor. The OTS-Scan can provide an original CGP if a patient comes with no CGP results. The OTS-Select chooses matched somatic mutations from our dPCR probe library. The OTS-Monitor quantifies VAFs of ctDNA periodically in the patient plasma with a sensitivity of 0.05% VAF. There is no strict patient eligibility criteria other than the requirement of previous therapy for treatment of an advanced cancer. Results: Between April and November 2022, 26 patients visited Iwate Medical University Hospital for the OTS-Assay. Twenty-five patients were referred from other Departments of Iwate Medical University Hospital. The primary cancer types include esophagus (n=21), colorectal (n=2), pancreas (n=2), and breast (n=1). Twenty patients had CGP results at their first visit. OTS-Select were used for 13 patients and picked an average of 11.4 mutations per patient. Among those, each of eight patients were immediately able to start ctDNA monitoring with one of the 1000 dPCR probes. As of November 2022, there are four patients who received OTS-Monitor more than one time. Any unexpected VAF increase of ctDNA has not been noted, although a substantial decrease of ctDNA VAF was found in one patient who received one cycle of chemotherapy. Conclusion: The OTS-Assay is a practical introduction of our previous clinical research products based on a core technology, which uses an originally developed library of &amp;gt;1000 dPCR probes. The potential of early and accurate MRD detection will improve post-treatment cancer patient management. Citation Format: Satoshi S. Nishizuka, Hayato Hiraki, Masakazu Abe, Akiko Yashima-Abo, Takeshi Iwaya. An introduction of a highly sensitive circulating tumor DNA monitoring system for minimal residual disease detection using a library of 1000 digital PCR probes. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5599.

Tumor Marker in Early Detection of Malignancies in Type 2 Diabetes: A Case Series Analysis

Abstract The association between type 2 diabetes mellitus (T2DM) and malignancy has gained significant attention, with a heightened susceptibility to specific cancers. We present a comprehensive case series, documenting four distinctive cases illustrating the critical role of tumor markers in early cancer detection among patients with T2DM. Our findings emphasize the significance of vigilant surveillance and comprehensive patient care in the timely diagnosis and management of malignancies. The cases highlight the utility of tumor markers, particularly carbohydrate antigen 19-9, in the identification of pancreatic adenocarcinoma, lung cancer, and prostate cancer. These markers facilitated early interventions and subsequent tailored treatments, resulting in improved patient outcomes and extended survival. In addition, we underscore the challenges encountered in clinical practice, emphasizing the need for effective patient education and engagement in decision-making processes regarding their health. Although not currently recommended as routine screening tools, the potential lifesaving impact of tumor marker screenings in asymptomatic high-risk patients with T2DM warrants further consideration and research. This case series serves to underscore the critical role of tumor markers in uncovering potential malignancies at early stages, ultimately improving patient outcomes and quality of life.

Synthesis of uniform Pickering microspheres doped with quantum dot by microfluidic technology and its application in tumor marker

Tumor markers play a significant role in early cancer diagnosis, evaluation of the extent of the disease, and monitoring of therapy response. In this study, we described the Pickering emulsion polymerization method to synthesize uniform magnetic/fluorescent microspheres. A Pickering-structure composed of a lot silica nanoparticle closely covered onto the quantum dot-encoded magnetic microbeads is designed and synthesized. The uniform magnetic/fluorescent microspheres were prepared using a microfluidic device and the performance of the microspheres synthesized by the instruments was evaluated by flow cytometry. To avoid fluorescence quenching and intrinsic toxicity, CdSe/ZnS core-shell quantum dot and Fe3O4 nanoparticle were successfully encapsulated into MFM microspheres using the microfluidic technology. Using this structure enables the facile realization of a theoretical 4 × 4 barcoding matrix combining two colors and four fluorescence intensity levels. Then, different optical codes were prepared by simple changing the emission wavelength and the intensity of the quantum dots. The resulting microsphere are combined with flow cytometer using two lasers for decoding of multiplex tumor markers. Moreover, the stability testing of microspheres demonstrated good performance for further application in detection of tumor markers as well. When applied for the high-throughput ultrasensitive detection of three tumor markers (CEA, CA125 and CA199) in a single sample, the detection limits of 0.027 ng/mL for CEA, 1.48 KU/L for CA125 and 1.09 KU/L for CA199 are achieved, which exhibit superior detection performance. Thus, Pickering-structure magnetic/fluorescent microspheres are promising for application in tumor markers.

Study on the diagnostic value of VEGF, CA19-9 and CEA in pancreatic cancer and the risk factors of vascular invasion

Background: Pancreatic cancer is a malignant tumor of the gastrointestinal tract. Due to its insidious onset, most patients with newly diagnosed pancreatic cancer have missed the opportunity for radical surgery, which offers patients the best chance of survival. The 5-year survival rate of patients with pancreatic cancer can be improved with early diagnosis, and serum tumor makers are an inexpensive and convenient diagnostic tool that is widely used in the diagnosis of malignancies. Objective: To determine the diagnostic value of vascular endothelial growth factor (VEGF), carbohydrate antigen 19-9 (CA 19-9), and carcinoembryonic antigen (CEA) in patients with pancreatic cancer and the risk factors of vascular invasion. Methods: An experimental group comprising 52 patients with pancreatic cancer admitted to our department from July 2021 to July 2022 and a control group comprising 21 patients with benign pancreatic diseases during the same period were included in our study. Their serum VEGF, CA 19-9, and CEA levels were detected and compared between the two groups, and the correlation between the three markers in the invaded vessel and non-invaded vessel groups was investigated. The diagnostic value of a single tumor marker and in combination for pancreatic cancer was analyzed, and the three tumor marker levels of the experimental group in different pathological characteristics were detected and compared. Results: The experimental group had higher serum VEGF, CA 19-9, and CEA levels than the control group (P &lt; 0.05). Through a receiver operating characteristic (ROC) curve analysis, the combined detection had the highest value for the diagnosis of pancreatic cancer, in which the area under the curve (AUC) was 0.9158 (95% CI: 0.8415–0.9900), while the sensitivity and specificity were 76.19% and 98.08%, respectively. Serum VEGF and CA 19-9 levels were higher in stage III–IV pancreatic cancer patients and those with tumor metastasis compared with stage I–II patients and those without metastasis (P &lt; 0.05), respectively. Binary logistic regression analysis was performed to determine the risk factors of vascular invasion in pancreatic cancer, and the results showed that only serum VEGF was a risk factor (P &lt; 0.05), OR (95% CI): 1.001–1.006. Conclusion: Patients with pancreatic cancer have significantly higher serum VEGF, CA 19-9, and CEA levels, and the combined detection of tumor markers is of high clinical value in its diagnosis. In addition, serum VEGF is an independent risk factor of vascular invasion in pancreatic cancer, which can predict vascular invasion to a certain extent.

Ultrasensitive miRNA-21 Biosensor Based on Zn(TCPP) PET-RAFT Polymerization Signal Amplification and Multiple Logic Gate Molecular Recognition

Quantitative measurement of microRNAs (miRNAs) is extremely important in plenty of biomedical applications especially cancer diagnosis but remains a great challenge. In this work, we developed a logic gate recognition biosensing platform based on the "trinity" molecular recognition mode for quantifying miRNAs with a detection limit of 4.48 aM, along with a linear range from 0.1 nM to 10 aM under optimal experimental conditions. In order to obtain excellent detection performance, we adopted a Zn(TCPP) photocatalytic electron transfer reversible addition-fragmentation chain transfer (PET-RAFT) polymerization signal amplification strategy. The light-induced PET-RAFT has developed green applications of free radical polymerization in the field of biosensors. This is the first report on the preparation of signal amplification biosensors using PET-RAFT for tumor marker detection. With the outstanding detection performance, we can apply the sensor system to the early screening of lung cancer patients.

Antígeno prostático específico en adultos de las parroquias urbanas de Cuenca - Ecuador

The objective of this research was to determine the values of prostate-specific antigen (PSA) in the blood serum of 1100 adults aged 40 to 80 who reside in the urban parishes of the city of Cuenca during 2018. The micro ELISA technique was used to determine PSA values, a glycoprotein secreted by the prostatic epithelium that allows sperm liquefaction and spermatozoa mobility. The results revealed that 8% of patients had values higher than 4 ng/ml, considered as the maximum limit of normality and present in prostatitis, benign prostatic hyperplasia, and prostate cancer. 50% of positive cases belonged to the age group of 70 to 80 years, finding statistical significance (p&lt;0.05) when related to variables such as age, family history, and sexual activity, highlighting the importance of establishing periodic control of this tumor marker for early detection.

Surface Plasmon Resonance (SPR) Sensor for Cancer Biomarker Detection

A biomarker is a physiological observable marker that acts as a stand-in and, in the best-case scenario, forecasts a clinically significant outcome. Diagnostic biomarkers are more convenient and cost-effective than directly measuring the ultimate clinical outcome. Cancer is among the most prominent global health problems and a major cause of morbidity and death globally. Therefore, cancer biomarker assays that are trustworthy, consistent, precise, and verified are desperately needed. Biomarker-based tumor detection holds a lot of promise for improving disease knowledge at the molecular scale and early detection and surveillance. In contrast to conventional approaches, surface plasmon resonance (SPR) allows for the quick and less invasive screening of a variety of circulating indicators, such as circulating tumor DNA (ctDNA), microRNA (miRNA), circulating tumor cells (CTCs), lipids, and proteins. With several advantages, the SPR technique is a particularly beneficial choice for the point-of-care identification of biomarkers. As a result, it enables the timely detection of tumor markers, which could be used to track cancer development and suppress the relapse of malignant tumors. This review emphasizes advancements in SPR biosensing technologies for cancer detection.

Nontoxic Fluorescent Nanoprobes for Multiplexed Detection and 3D Imaging of Tumor Markers in Breast Cancer

Multiplexed fluorescent immunohistochemical analysis of breast cancer (BC) markers and high-resolution 3D immunofluorescence imaging of the tumor and its microenvironment not only facilitate making the disease prognosis and selecting effective anticancer therapy (including photodynamic therapy), but also provides information on signaling and metabolic mechanisms of carcinogenesis and helps in the search for new therapeutic targets and drugs. The characteristics of imaging nanoprobe efficiency, such as sensitivity, target affinity, depth of tissue penetration, and photostability, are determined by the properties of their components, fluorophores and capture molecules, and by the method of their conjugation. Regarding individual nanoprobe components, fluorescent nanocrystals (NCs) are widely used for optical imaging in vitro and in vivo, and single-domain antibodies (sdAbs) are well established as highly specific capture molecules in diagnostic and therapeutic applications. Moreover, the technologies of obtaining functionally active sdAb-NC conjugates with the highest possible avidity, with all sdAb molecules bound to the NC in a strictly oriented manner, provide 3D-imaging nanoprobes with strong comparative advantages. This review is aimed at highlighting the importance of an integrated approach to BC diagnosis, including the detection of biomarkers of the tumor and its microenvironment, as well as the need for their quantitative profiling and imaging of their mutual location, using advanced approaches to 3D detection in thick tissue sections. The existing approaches to 3D imaging of tumors and their microenvironment using fluorescent NCs are described, and the main comparative advantages and disadvantages of nontoxic fluorescent sdAb-NC conjugates as nanoprobes for multiplexed detection and 3D imaging of BC markers are discussed.

Construction of an electrochemical immunosensor based on the OER signal of Au@CoFe-(oxy)hydroxide for ultrasensitive detection of CEA

Carcinoembryonic antigen (CEA) is a group of glycoproteins highly associated with cell adhesion and is an important antigen as a tumor biomarker commonly used in clinical diagnosis. Therefore, CEA detection plays a significant role in early clinical tumor diagnosis. In this study, an electrocatalytic signal labeled immunosensor was constructed for CEA ultrasensitive detection. We use a core–shell Au@CeO2 modified glassy carbon electrode (GCE) to capture more primary antibody (Ab1). The core–shell structure captures Ab1 through Au-S and OC–O bonds, providing more binding sites and a more stable binding force for Ab1. Because of the large specific surface area of the Au@CoFe-(oxy)hydroxide nanosheets and its outstanding oxygen evolution reaction (OER) signal under neutral medium, Au@CoFe-(oxy)hydroxide combined with secondary antibody (Ab2) as the signal tag and signal amplifier of the sensor. The proposed electrochemical immunosensor exhibited a good linear response from 0.0001 ng mL−1 to 200 ng mL−1 and a low detection limit of 0.0534 pg mL−1. The effectiveness of the sensor is verified by the standard addition method. This work provides a novel research approach for the clinical detection of tumor markers.

Versatile fluorescence detection of T4 PNK and mRNA based on unique DNA nanomachine amplification

The development of DNA nanomachines provides a new strategy for the detection of tumor markers. In this work, an intelligent three-dimensional (3D) DNA walking machine with polynucleotide kinase (PNK) activator was designed, which was coupled with unique nanomachine formed by DNA nanowire cascade amplification reaction for versatile fluorescence detection of T4 PNK activity and messenger RNA (mRNA). When PNK exists, the free DNA walker was formed by hydrolysis cleavage of exonuclease, then the fluorophore-labeled report probe on the Au nanoparticles (NPs) was sheared during cycling cleavage reaction, thus the fluorescence signal was recovered for detection of PNK. Moreover, the DNA nanowires were produced by rolling ring amplification, then target mRNA sequentially initiated interval hybridization of hairpin probes through DNA nanowire, thus realizing DNA cascade reaction (DCR) with high “on” signal of DNA nanomachine for mRNA assay. This developed novel fluorescence nanomachine reported a new assay method with promising application for versatile targets and showed great potential for molecular-target therapies, and clinic diagnostics.

Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer

Immunotherapy based on immune checkpoint inhibitors (ICIs) has provided revolutionary results in treating various cancers. However, its efficacy in colorectal cancer (CRC), especially in microsatellite stability-CRC, is limited. This study aimed to observe the efficacy of personalized neoantigen vaccine in treating MSS–CRC patients with recurrence or metastasis after surgery and chemotherapy. Candidate neoantigens were analyzed from whole-exome and RNA sequencing of tumor tissues. The safety and immune response were assessed through adverse events and ELISpot. The clinical response was evaluated by progression-free survival (PFS), imaging examination, clinical tumor marker detection, circulating tumor DNA (ctDNA) sequencing. Changes in health-related quality of life were measured by the FACT-C scale. A total of six MSS–CRC patients with recurrence or metastasis after surgery and chemotherapy were administered with personalized neoantigen vaccines. Neoantigen-specific immune response was observed in 66.67% of the vaccinated patients. Four patients remained progression-free up to the completion of clinical trial. They also had a significantly longer progression-free survival time than the other two patients without neoantigen-specific immune response (19 vs. 11 months). Changes in health-related quality of life improved for almost all patients after the vaccine treatment. Our results shown that personalized neoantigen vaccine therapy is likely to be a safe, feasible and effective strategy for MSS–CRC patients with postoperative recurrence or metastasis.

AIEgens-Doped Photonic Crystals for High Sensitivity Fluorescence Detection of Tumor Markers

Detection of tumor markers is of great significance to preliminarily judge whether patients have malignant tumors. Fluorescence detection (FD) is an effective means to achieve sensitive detection of tumor markers. Currently, the increased sensitivity of FD has attracted research interest worldwide. Here, we have proposed a method of doping luminogens with aggregation-induced emission (AIEgens) into photonic crystals (PCs), which can significantly enhance the fluorescence intensity to achieve high sensitivity in the detection of tumor markers. PCs are made by scraping and self-assembling, which has the special effect of fluorescence enhancement. The combination of AIEgens and PCs can enhance the fluorescence intensity 4-7 times. These characteristics make it extremely sensitive. The limit of detection (LOD) for the detection of alpha-fetoprotein (AFP) in the AIE10 (Tetraphenyl ethylene-Br) doped PCs with a reflection peak of 520 nm is 0.0377 ng/mL. LOD for the detection of carcinoembryonic antigen (CEA) in the AIE25 (Tetraphenyl ethylene-NH2) doped PCs with a reflection peak of 590 nm is 0.0337 ng/mL. Our concept offers a good solution for highly sensitive detection of tumor markers.

Magnetic quantum dots barcodes using Fe3O4/TiO2 with weak spectral absorption in the visible region for high-sensitivity multiplex detection of tumor markers

Magnetic quantum dot (QD) barcode holds great potential for automatic suspension array and rapid point-of-care detection since it enables simultaneous target encoding, enrichment and separation. However, a serious obstacle to enhancing the encoding capacity of magnetic QD microbeads (MBs) is the fluorescence quenching of magnetic nanoparticles (MNPs) to quantum dots (QDs) in the visible wavelength range due to the broad and strong optical absorption spectrum of MNPs. Here, we report Fe3O4/TiO2 core/shell MNPs and CdSe/ZnS QDs for the construction of dual-function magnetic QD barcodes. Fe3O4/TiO2 MNPs can significantly inhibit fluorescence quenching because the weak absorption of visible light by the TiO2. The two-dimension barcode library of 30 magnetic QD barcodes was constructed based on Fe3O4/TiO2 MNPs and CdSe/ZnS QDs. Moreover, the magnetic QD barcodes showed high sensitivity for the multiplex detection of four tumor markers, cancer antigen 125 (CA125), cancer antigen 199 (CA199), alpha-fetoprotein (AFP), and neuron specific enolase (NSE) with detection limits of 0.89 KU/L, 0.72 KU/L, 0.05 ng/mL, and 0.15 ng/mL, respectively. This bifunctional magnetic QD barcodes are promising for automatic high-sensitivity multiplex bioassay.

An ultrasensitive electrochemical immunosensor for CA72-4 based on a signal amplification strategy of MoS2 nanoflower-supported Au nanoparticles

Accurate detection of cancer antigen 72-4 (CA72-4), a tumor-associated glycoprotein, is of great significance for gastric cancer diagnosis and immunotherapy monitoring. Modification of noble metal nanoparticles on transition metal dichalcogenides can significantly enhance functions, such as electron transport. Molybdenum disulfide gold nanoparticles nanocomposites (MoS2-Au NPs) were prepared in this study and a series of characterization studies were carried out. In addition, a label-free, highly sensitive electrochemical immunosensor molybdenum disulfide -Au nanoparticles/Glassy carbon electrode (MoS2-Au NPs/GCE) was also prepared and used for the detection of CA72-4. The electrochemical performance of the immunosensor was characterized by electrochemical techniques, such as cyclic voltammetry (CV), differential pulse voltammetry (DPV), and electrochemical impedance spectroscopy (EIS). The results indicated that better MoS2-Au NPs nanomaterials have been synthesized, and the prepared electrochemical immunosensor, MoS2-Au NPs/GCE, showed excellent electrochemical performance. The sensor exhibited high detection sensitivity under optimal conditions, including an incubation time of 30 min, an incubation temperature of 25 °C, and a pH of 7.0. The electrochemical immunosensor also had a low detection limit of 2.0 × 10−5 U/mL (S/N = 3) in a concentration range of 0.001–200 U/mL, with good selectivity, stability, and repeatability. In conclusion, this study provided a theoretical basis for the highly sensitive detection of tumor markers in clinical biological samples.

Mean platelet volume/platelet count ratio in combination with tumor markers in colorectal cancer: a retrospective clinical study

BackgroundMean platelet volume (MPV) is a marker of platelet activation, which is usually negatively correlated with platelet count (PC). The ratio of MPV to PC (MPV/PC) has an essential role in the diagnosis of multiple malignancies. However, only a few studies investigated the value of MPV/PC in colorectal cancer (CRC) and the combination of MPV/PC with tumor markers in CRC. This retrospective clinical study aimed to evaluate the diagnostic value of MPV/PC and tumor markers (CA72-4, CA125, CA199) used alone or in combination in CRC.Methods200 patients with CRC and 317 patients with colorectal benign polypus pathologically diagnosed during 2019/01/04 to 2022/06/30 were included. Hematological and pathological parameters of the above patients were collected, data were analyzed with Student’s t-test, one-way ANOVA or Kruskal-Wallis H test and receiver operating characteristic (ROC) curve, and ROC curve was used to evaluate the diagnostic value of tumor markers and MPV/PC used alone or in combination in CRC.ResultsThe MPV/PC in CRC group was significantly lower than the control group (P < 0.0001). Among the three tumor markers, higher CA125 was correlated with distant metastasis and lower differentiation (P < 0.05), increased CA72-4 indicated positive nerve invasion (P = 0.0174), and elevated CA199 was associated with lymphatic metastasis and positive vascular invasion (P < 0.05). For subgroups regarding tumor anatomical location, both CA125 and CA199 were higher in colon cancer group than rectum cancer group (P = 0.0322, P = 0.0094). MPV/PC was associated with tumor infiltration, regional lymph node metastasis, differentiation and nerve invasion (P < 0.05) and the combination of MPV/PC with the three tumor markers produced a larger AUC with higher sensitivity, specificity and Yuden index than MPV/PC or the three tumor markers used alone to distinguish between CRC and colorectal polyps.ConclusionPreoperative MPV/PC in peripheral blood of patients with CRC was lower than the control group. Meanwhile, the combined detection of tumor markers with MPV/PC can improve the diagnostic value of CRC, revealing the potential of MPV/PC as a promising screening tool in CRC early diagnosis.